Serina Therapeutics, Inc. (SER) News
Track canonical SquawkNews coverage tagged to SER, Serina Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Serina Therapeutics reports Q2 2026 financial results, issues business updates
Serina Therapeutics reports its second quarter 2026 financial results and provides business updates, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:16 PM UTC
H
Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease
() -- Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a rev
EARNINGS | Jul 09, 2026, 04:40 PM UTC
L
BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8
BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX: SER ) with a Buy rating and announces Price Target of $8.
EQUITY | Jul 01, 2026, 11:54 AM UTC